Association between serum perfluorooctanoic acid (PFOA) and thyroid disease in the U.S. National Health and Nutrition Examination Survey

Environmental Health Perspectives

Volumn 118, Issue 5, 2010, Pages 686-692

  Melzer, David ^a   Rice, Neil ^a   Depledge, Michael H ^a   Henley, William E ^b   Galloway, Tamara S ^c  

^a PENINSULA MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF PLYMOUTH   (United Kingdom)

^c UNIVERSITY OF EXETER   (United Kingdom)

Author keywords

C8; Human population; PFOA; PFOS; Thyroid disease

Indexed keywords

PERFLUOROOCTANESULFONIC ACID; PERFLUOROOCTANOIC ACID;

ADULT; AGE; AGED; ALCOHOL CONSUMPTION; ARTICLE; BLOOD LEVEL; BODY MASS; CIGARETTE SMOKING; CONTROLLED STUDY; EDUCATIONAL STATUS; ETHNICITY; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE; THYROID DISEASE; UNITED STATES;

ADULT; AGED; ALKANESULFONIC ACIDS; ANIMALS; CROSS-SECTIONAL STUDIES; ENDOCRINE DISRUPTORS; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL POLLUTANTS; FEMALE; FLUOROCARBONS; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; OCTANOIC ACIDS; RISK ASSESSMENT; THYROID DISEASES; UNITED STATES; YOUNG ADULT;

ANIMALIA;

EID: 77951707570     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.0901584     Document Type: Article

References (58)

1. Barter R, Klaassen C. 1994. Reduction of thyroid hormone levels and alteration of thyroid function by four representative UDP-glucuronosyl transferase inducers in rats. Toxicol Appl Pharmacol 128:9-17.
2. Boas M, Feldt-Rasmussen U, Skakkebaek N, Main K. 2006. Environmental chemicals and thyroid function Eur J Endocrinol 154:599-611.
3. Butenhoff J, Costa G, Elcombe C, Farrar D, Hansen K, Iwai H, et al. 2002. Toxicity of ammonium perfluorooctanoate in male cynomolgus monkeys after oral dosing for 6 months. Toxicol Sci 69:244-257.
4. Calafat AM, Kuklenyik Z, Caudill SP, Reidy JA, Needham LL. 2006. Perfluorochemicals in pooled serum samples from United States residents in 2001 and 2002. Environ Sci Technol 40(7):2128-2134.
5. Calafat AM, Wong LY, Kuklenyik Z, Reidy JA, Needham LL. 2007. Polyfluoroalkyl chemicals in the U.S. population: data from the National Health and Nutrition Examination Survey (NHANES) 2003-2004 and comparisons with NHANES 1999-2000. Environ Health Perspect 115:1596-1602.
6. C8 Science Panel. 2009. Cross Sectional Study of C8 and Immune Function, Hematopoietic Function, Liver, Kidney, and Endocrine Disorders and Cancer Prevalence-a Prevalence Study among Participants in the C8 Health Project [abstract]. Available: http://www.C8sciencepanel.org/studies.html#2 [accessed 10 October 2009].
7. C8 Science Panel. 2008. Status Report: Factors Associated with PFOA Levels in a Community Surrounding a Chemical Plant. Available: http://c8sciencepanel.org/pdfs/Status_Report-factors_associated_with_C8_levels_Oct2008.pdf [accessed accessed 10 October 2009].
8. Chang S, Hart J, Ehresman D, Das K, Lau C, Noke P, et al. 2007. The pharmacokinetics of perfluorobutyrate in rats, mice and monkeys. Toxicologist 96:194-202.
9. Chen Y, Guo L. 2009. Fluorescence study on site-specific binding of perfluoroalkyl acids to human serum albumin. Arch Toxicol 83:255-261.
10. Emmett EA, Zhang H, Shofer FS, Freeman D, Rodway NV, Desai C, et al. 2006. Community exposure to perfluorooctanoate: relationships between serum levels and certain health parameters. J Occup Environ Med 48(8):771-779.
11. Felt-Rasmussen U, Hyltoft P, Blaabjerg O, Horder M. 1980. Long term variability in serum thyroglobulin and thyroid related hormones in healthy subjects. Acta Endocrinol (Copenh) 95:328-334.
12. Ferreira AC, Lisboa PC, Oliveira KJ, Lima LP, Barros IA, Carvalho DP. 2002. Inhibition of thyroid type 1 deiodinase activity by flavonoids. Food Chem Toxicol 40(7):913-917.
13. Fromme H, Tittlemier SA, Volkel W, Wilhelm M, Twardella D. 2009. Perfluorinated compounds-exposure assessment for the general population in Western countries. Int J Hyg Environ Health 212(3):239-270.
14. Ghisari M, Bonefeld-Jorgensen EC. 2005. Impact of environmental chemicals on the thyroid hormone function in pituitary rat GH3 cells. Mol Cell Endocrinol 244(1-2):31-41.
15. Giesy J, Kannan, K. 2001. Global distribution of perfluorooctanoate sulfonate in wildlife. Environ Sci Technol 35:1339-1342.
16. Gutshall DM, Pilcher GD, Langley AE. 1988. Effect of thyroxine supplementation on the response to perfluoro-n-decanoic acid (PFDA) in rats. J Toxicol Environ Health 24(4):491-498.
17. Gutshall DM, Pilcher GD, Langley AE. 1989. Mechanism of the serum thyroid hormone lowering effect of perfluoro-n-decanoic acid (PFDA) in rats. J Toxicol Environ Health 28(1):53-65.
18. Hsieh FY, Bloch DA, Larsen MD. 1998. A simple method of sample size calculation for linear and logistic regression. Stat Med 17(14):1623-1634.
19. Hundley S, Sarrif A, Kennedy G. 2006. Absorption, distribution and excretion of ammonium perfluorooctanoate (APFO) after oral administration in various species. Drug Chem Toxicol 29:137-145.
20. Inoue K, Okada F, Ito R, Kato S, Sasaki S, Nakajima S, et al. 2004. Perfluorooctane sulfonate (PFOS) and related perfluorinated compounds in human maternal and cord blood samples: assessment of PFOS exposure in a susceptible population during pregnancy. Environ Health Perspect 112:1204-1207.
21. Jensen AA, Leffers H. 2008. Emerging endocrine disrupters: perfluoroalkylated substances. Int J Androl 31(2):161-169.
22. Johnson J, Gibson S, Ober R. 1979. Extent and Route of Excretion and Tissue Distribution of Total Carbon-14 in Rats after a Single i.v. Dose of FC-95-14C. Washington, DC:U.S. Environmental Protection Agency.
23. Jones P, Hu W, De coen W, Newsted J, Giesy J. 2003. Binding of perfluorinated fatty acids to serum proteins. Environ Toxicol Chem 22:2639-2649.
24. Kannan K, Corsolini S, Falandysz J, Fillmann G, Kumar KS, Loganathan BG, et al. 2004. Perfluorooctanesulfonate and related fluorochemicals in human blood from several countries. Environ Sci Technol 38(17):4489-4495.
25. Kohrle J, Spanka M, Irmscher K, Hesch R. 1988. Flavonoid effects on transport, metabolism and action of thyroid hormones. Prog Clin Bio Res 280:323-340.
26. Kuklenyik Z, Needham LL, Calafat AM. 2005. Measurement of 18 perfluorinated organic acids and amides in human serum using on-line solid-phase extraction. Anal Chem 77(18):6085-6091.
27. Langley AE, Pilcher GD. 1985. Thyroid, bradycardic and hypothermic effects of perfluoro-n-decanoic acid in rats. J Toxicol Environ Health 15(3-4):485-491.
28. Lau C, Anitole K, Hodes C, Lai D, Pfahles-Hutchens A, Seed J. 2007 Perfluoroalkyl acids: a review of monitoring and toxicological findings. Toxicol Sci 99(2):366-394.
29. Lau C, Butenhoff JL, Rogers JM. 2004. The developmental toxicity of perfluoroalkyl acids and their derivatives. Toxicol Appl Pharmacol 198(2):231-241.
30. Lau C, Thibodeaux J, Hanson R, Rogers J, Grey B, Stanton M, et al. 2003. Exposure to perfluorooctane sulfonate during pregnancy in rat and mouse. II: Postnatal evaluation. Toxicol Sci 74:382-392.
31. Luebker DJ, Case MT, York RG, Moore JA, Hansen KJ, Butenhoff JL. 2005. Two-generation reproduction and cross-foster studies of perfluorooctanesulfonate (PFOS) in rats. Toxicology 215(1-2):126-148.
32. Luebker DJ, Hansen KJ, Bass NM, Butenhoff JL, Seacat AM. 2002. Interactions of flurochemicals with rat liver fatty acid-binding protein. Toxicology 176(3):175-185.
33. Minnesota Department of Health. 2008. Health Risk Limits for Perfluorochemicals. Report to the Minnesota Legislature 2008, Minnesota Department of Health Final Report. Available: http://www.health.state.mn.us/divs/eh/hazardous/topics/pfcs/finalreport011508.pdf [accessed 10 October 2009].
34. Moriyama K, Tagami T, Akamizu T, Usui T, Saijo M, Kanamoto N, et al. 2002. Thyroid hormone action is disrupted by bisphenol A as an antagonist. J Clin Endocrinol Metab 87(11):5185-5190.
35. NCHS (National Center for Health Statistics). 2009. National Health and Nutrition Examination Survey: Lab Methods 2005-2006. Available: http://www.cdc.gov/nchs/data/nhanes/nhanes_05_06/pfc_d_met.pdf [accessed 2 October 2009].
36. NHANES. 2006. Documentation, Codebook, and Frequencies. Surplus Specimen Laboratory Component: Perfluorinated Chemicals (Surplus Sera). National Health and Nutrition Examination Survey. Available: http://www.cdc.gov/nchs/data/nhanes/frequency/sspfc_a.pdf [accessed 2 October 2009].
37. NHANES. 2007. Documentation, Codebook, and Frequencies. Laboratory Component: Polyfluorinated Compounds. Available: http://www.cdc.gov/nchs/data/nhanes/nhanes_03_04/l24pfc_c.pdf [accessed 2 October 2009].
38. Olsen GW, Burlew M, Burris J, Mandel J. 2001. A Cross-Sectional Analysis of Serum Perfluorooctanesulfonate (PFOS) and Perfluorooctanoate (PFOA) in Relation to Clinical Chemistry, Thyroid Hormone, Hematology and Urinalysis Results from Male and Female Employee Participants of the 2000 Antwerp and Decatur Fluorochemical Medical Surveillance Program 3M Company. Final Report. Administrative Record AR-226-1087. Washington, DC:U.S. Environmental Protection Agency.
39. Olsen GW, Burris JM, Burlew MM, Mandel JH. 2003a. Epidemiologic assessment of worker serum perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) concentrations and medical surveillance examinations. J Occup Environ Med 45(3):260-270.
40. Olsen GW, Burris JM, Ehresman DJ, Froehlich JW, Seacat AM, Butenhoff JL, et al. 2007. Half-life of serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers. Environ Health Perspect 115:1298-1305.
41. Olsen G, Church T, Miller J, Burris J, Hansen K, Lundberg J, et al. 2003b. Perfluorooctanosulfonate (PFOS) and other fluorochemicals in the serum of American Red Cross adult blood donors. Environ Health Perspect 111:1892-1902.
42. Olsen GW, Logan PW, Hansen KJ, Simpson CA, Burris JM, Burlew MM, et al. 2003c. An occupational exposure assessment of a perfluorooctanesulfonyl fluoride production site: biomonitoring. AIHA J (Fairfax, Va) 64(5):651-659.
43. Olsen G, Zobel L. 2007. Assessment of lipid, hepatic and thyroid parameters with serum perfluorooctanoate (PFOA) concentrations in fluorochemical production workers. Int Arch Occup Environ Health 81:231-246.
44. Organisation for Economic Co-operation and Development. 2005. Results of Survey on Production and Use of PFOS and PFOA, Related Substances and Products/Mixtures Containing These Substances. Paris:Organisation for Economic Co-operation and Development.
45. Saito N, Harada K, Inoue K, Sasaki K, Yoshinaga T, Koizumi A. 2004. Perfluorooctanoate and perfluorooctane sulfonate concentrations in surface water in Japan. J Occup Health 46:49-59.
46. Santini F, Vitti P, Ceccarini G, Mammoli C, Rosellini V, Pelosini C, et al. 2003. In vitro assay of thyroid disruptors affecting TSH-stimulated adenylate cyclase activity. J Endocrinol Invest 26(10): 950-955.
47. Schmutzler C, Gotthardt I, Hofmann PJ, Radovic B, Kovacs G, Stemmler L, et al. 2007. Endocrine disruptors and the thyroid gland-a combined in vitro and in vivo analysis of potential new biomarkers. Environ Health Perspect 115(suppl 1):77-83.
48. Schröder-van der Elst JP, Smit JW, Romijn HA, van der Heide D. 2003. Dietary flavonoids and iodine metabolism. Biofactors 19:171-176.
49. Scialli A, Iannucci A, Turi J. 2007. Combining perfluoroalkane acid exposure levels for risk assessment. Reg Toxicol Pharmacol 49:195-202.
50. Seacat AM, Thomford PJ, Hansen KJ, Clemen LA, Eldridge SR, Elcombe CR, et al. 2003. Sub-chronic dietary toxicity of potassium perfluorooctanesulfonate in rats. Toxicology 183(1-3):117-131.
51. Steenland KJ, MacNeil J, Lally C, Lally A, Vieira V, Fletcher T. 2009. Predictors of PFOA levels in a community surrounding a chemical plant. Environ Health Perspect 117:1083-1088.
52. Stockholm Convention on Persistent Organic Pollutants. 2008. Home page. Available: http://chm.pops.int/ [accessed 2 October 2009].
53. U.S. EPA. 2006. The 2010/2015 PFOA Stewardship Program. Available: http://www.epa.gov/oppt/pfoa/pubs/stewardship/index.html [accessed 10 October 2009].
54. Vanden Huevel J, Thompson J, Frame S, Gillies P. 2006. Differential activation of nuclear receptors by perfluorinated fatty acid analogues and natural fatty acid. Toxicol Sci 92:476-489.
55. vom Saal FS, Hughes C. 2005. An extensive new literature concerning low-dose effects of bisphenol A shows the need for a new risk assessment. Environ Health Perspect 113:926-933.
56. Weineke N, Neuschafer-Rube F, Bode L, Kuna M, Andres J, Carnevali L, et al. 2009. Synergistic acceleration of thyroid hormone degradation by phenobarbitol and the peroxisome proliferation receptor agonist WY14643. Toxicol Appl Pharmacol 240:99-107.
57. Welshons WV, Thayer KA, Judy BM, Taylor JA, Curran EM, vom Saal FS. 2003. Large effects from small exposures. I. Mechanisms for endocrine-disrupting chemicals with estrogenic activity. Environ Health Perspect 111:994-1006.
58. Yu WG, Liu W, Jin YH. 2009. Effects of perfluorooctane sulfonate on rat thyroid hormone biosynthesis and metabolism. Environ Toxicol Chem 28(5):990-996.